Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Myriad Genetics (MYGN) Change in Taxes (2016 - 2025)

Myriad Genetics (MYGN) has disclosed Change in Taxes for 16 consecutive years, with -$1.8 million as the latest value for Q4 2025.

  • On a quarterly basis, Change in Taxes fell 200.0% to -$1.8 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$4.4 million, a 780.0% decrease, with the full-year FY2025 number at -$4.4 million, down 780.0% from a year prior.
  • Change in Taxes was -$1.8 million for Q4 2025 at Myriad Genetics, down from -$500000.0 in the prior quarter.
  • In the past five years, Change in Taxes ranged from a high of $18.1 million in Q4 2021 to a low of -$90.3 million in Q1 2021.
  • A 5-year average of -$5.7 million and a median of -$500000.0 in 2023 define the central range for Change in Taxes.
  • Peak YoY movement for Change in Taxes: plummeted 13000.0% in 2021, then soared 100.44% in 2022.
  • Myriad Genetics' Change in Taxes stood at $18.1 million in 2021, then tumbled by 101.1% to -$200000.0 in 2022, then tumbled by 150.0% to -$500000.0 in 2023, then fell by 20.0% to -$600000.0 in 2024, then crashed by 200.0% to -$1.8 million in 2025.
  • Per Business Quant, the three most recent readings for MYGN's Change in Taxes are -$1.8 million (Q4 2025), -$500000.0 (Q3 2025), and -$2.1 million (Q1 2025).